Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of PUL-042 Inhalation Solution in Healthy Subjects
NCT02124278Phase 1Completed
- Sponsor
- Pulmotect
- Start
- Feb 2014
- Primary completion
- Oct 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory tract infection (RTI) comparing PUL-042 with Placebo (2 arms). Primary endpoint: Dose-limiting toxicities. Started Feb 2014; status: completed.
02
Drugs
PUL-042
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT02124278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124278.